MockV Solutions Announces Presentation of Proof of Concept Data from its Mock Virus Particle Technology Platform at Upcoming Conferences in Fall 2018

Rockville, MD – September 24, 2018 MockV Solutions, Inc. (MockV), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that a poster abstract, submitted by collaborator MedImmune, has been accepted for presentation at Recovery of Biological Products XVIII Conference on October 7 – 12, 2018 in Ashville, N.C.  This poster will highlight results from a proof of concept study conducted between MedImmune, Texcell North America. and MockV, of the latter’s lead product, the MVM-MVP Kit.  In addition, a poster detailing this study will be presented at this year’s 3rd Annual Viral Clearance and Viral Safety Summit in San Francisco from October 9-10th.  Finally, an oral presentation highlighting results from a proof of concept study performed between Asahi Kasei, Texcell- North America and MockV will be delivered at this year’s 21st annual PlanovaTM Workshop in San Francisco on October 12th.  Details as follows:

Recovery of Biologicals Products XVIII

Presenter:   Joshua Orchard, Associate Scientist – MedImmune

Date: October 7-12th 2018

Poster Title: Using A Non-Infectious MVM Surrogate for Assessing Viral Clearance During      Downstream Process Development


3rd Annual Viral Clearance and Viral Safety Summit

Presenter:   Alysia Birkholz, Ph.D. Director, Research and Development – Texcell-North America

Date: October 9-10th 2018

Poster Title: Predicting MVM Clearance by Nanofiltration and Anion Exchange Chromatography Using a Non-Infectious “Mock Virus Particle”


21st Planova™ Workshop

Presenter:   David Cetlin, M.S.  CEO/Founder – MockV Solutions, Inc.

Date:   October 12th 2018

Presentation Title:   Use of A Non-Infectious Surrogate to Predict Minute Virus of Mice Removal During Nanofiltration


About Recovery of Biologicals Products XVIII

The Recovery of Biological Products Conference Series is the premier international forum for the presentation and discussion of recent advances in the operations used to recover biological products of therapeutic, diagnostic and industrial value to society. An invitation-only biennial event, the Conference Series provides delegates with a clear and comprehensive understanding of the status and direction of this fast-moving field.

Sponsored by the American Chemical Society, Division of Biochemical Technology (BIOT), this international conference provides exposure to the latest developments in bioprocessing with a focus on downstream processing and aspects that affect the downstream steps. Unparalleled opportunities to network with industry leaders are a key feature of the conference. The size, venue and schedule of the meeting are specifically designed to provide multiple opportunities for discussion and development of new areas and concepts relating to the separation, purification and efficient processing of biological products. The Conference Series is a Not-for-Profit 501(c) (3) organization.

More information can be found on their webpage:

About the 3rd Annual Viral Clearance and Viral Safety Summit

Sponsored by Charles River Laboratories, this 2-day summit brings together industry representatives, technology providers, and regulatory officials to explore trends, discuss challenges, and share tools for the successful implementation of a viral safety program into your product development. This summit will look at in vitro and in vivo viral safety assays along with viral clearance studies. Topics will range from viral safety for cell and gene therapy products to addressing viral clearance in continuous processing situations.

More information can be found on their webpage:

About the 21st Planova™ Workshop

Sponsored by Asahi Kasei Bioprocess, this workshop is an opportunity for Planova™ users to share experiences and to learn best practices of virus filtration. Event chairs and speakers at this annual event are key industry leaders in biotherapeutics, and their presentations cover topics such as tips for process optimization, validations, regulatory requirements and scaling up to commercial manufacturing. Event attendees are professionals in the fields of regulation, process development, pathogen safety, quality and manufacturing.

More information can be found on their webpage:

About MockV Solutions Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactive virus, a contaminant of great concern during the manufacturing of biopharmaceuticals.  These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging “spiking studies”. The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements – jeopardizing the timely approval of potentially life-altering therapies. MockV’s lead product candidate, the MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution.   For further information regarding MockV Solutions, Inc., please visit the Company’s website at

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and South San Francisco, CA. For more information, please visit

About Texcell-North America.

Texcell- North America is the United States based branch of Texcell, a global contract service organization located in Frederick, MD.  Texcell is committed to improving lives by supporting global therapeutic innovations. The organization provides custom cell culture, GMP cell banking, virus propagation, viral clearance, viral safety testing, toxicology, and immunology services.  For more information, please visit. |